title: [Efficiency therapy with rituximab in patients with non-Hodgkin's lymphomas].
abstract: Management of non-Hodgkin's lymphomas (NHL) has been significantly changed during last 40 years from radiotherapy to modern polychemotherapy with application of monoclonal antibodies. A ten year experience of the treatment of patients with B-cell NHL with rituximab application was accumulated in National Cancer Institute. The group of patients with NHL, who were treated in oncohematology department in the period from 2001 to 2010, was chosen for study of the efficacy of the treatment with rituximab. The immediate and distant results of the treatment were evaluated in this group of patients. The usage of the polychemotherapy with rituximab was highly efficient in the treatment of primary and relapsed patients with NHL. This group shows high rate of the immediate and distant results of treatment.
authors.forename: I A
authors.initials: IA
authors.lastname: Kriachok
authors.forename: K S
authors.initials: KS
authors.lastname: Filonenko
authors.forename: G O
authors.initials: GO
authors.lastname: Gubareva
authors.forename: I B
authors.initials: IB
authors.lastname: Tytorenko
authors.forename: O I
authors.initials: OI
authors.lastname: Novosad
authors.forename: T V
authors.initials: TV
authors.lastname: Kadnikova
authors.forename: O M
authors.initials: OM
authors.lastname: Aleksik
authors.forename: A V
authors.initials: AV
authors.lastname: Martynchyk
authors.forename: É V
authors.initials: ÉV
authors.lastname: Kushchevyĭ
authors.forename: Ia V
authors.initials: IaV
authors.lastname: Pastushenko
authors.forename: L B
authors.initials: LB
authors.lastname: Kutsenko
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology* / Q000378:metabolism; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000166:cytology / Q000276:immunology*; D001706:Biopsy; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D055502:Secondary Prevention; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology; D016896:Treatment Outcome; D014455:Ukraine
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab